Literature DB >> 25286977

Decade in review--clinical trials: shifting paradigms in cancer clinical trial design.

Daniel J Sargent1, Edward L Korn2.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25286977     DOI： 10.1038/nrclinonc.2014.167

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Design issues in randomized phase II/III trials.

Authors:  Edward L Korn; Boris Freidlin; Jeffrey S Abrams; Susan Halabi
Journal:  J Clin Oncol       Date:  2012-01-23       Impact factor: 44.544

2.  Design issues of randomized phase II trials and a proposal for phase II screening trials.

Authors:  Lawrence V Rubinstein; Edward L Korn; Boris Freidlin; Sally Hunsberger; S Percy Ivy; Malcolm A Smith
Journal:  J Clin Oncol       Date:  2005-10-01       Impact factor: 44.544

3.  I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy.

Authors:  A D Barker; C C Sigman; G J Kelloff; N M Hylton; D A Berry; L J Esserman
Journal:  Clin Pharmacol Ther       Date:  2009-05-13       Impact factor: 6.875

4.  Expediting drug development--the FDA's new "breakthrough therapy" designation.

Authors:  Rachel E Sherman; Jun Li; Stephanie Shapley; Melissa Robb; Janet Woodcock
Journal:  N Engl J Med       Date:  2013-11-14       Impact factor: 91.245

Review 5.  National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.

Authors:  Jeffrey Abrams; Barbara Conley; Margaret Mooney; James Zwiebel; Alice Chen; John J Welch; Naoko Takebe; Shakun Malik; Lisa McShane; Edward Korn; Mickey Williams; Louis Staudt; James Doroshow
Journal:  Am Soc Clin Oncol Educ Book       Date:  2014

6.  American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes.

Authors:  Lee M Ellis; David S Bernstein; Emile E Voest; Jordan D Berlin; Daniel Sargent; Patricia Cortazar; Elizabeth Garrett-Mayer; Roy S Herbst; Rogerio C Lilenbaum; Camelia Sima; Alan P Venook; Mithat Gonen; Richard L Schilsky; Neal J Meropol; Lowell E Schnipper
Journal:  J Clin Oncol       Date:  2014-03-17       Impact factor: 44.544

7.  The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.

Authors:  Lesley Seymour; S Percy Ivy; Daniel Sargent; David Spriggs; Laurence Baker; Larry Rubinstein; Mark J Ratain; Michael Le Blanc; David Stewart; John Crowley; Susan Groshen; Jeffrey S Humphrey; Pamela West; Donald Berry
Journal:  Clin Cancer Res       Date:  2010-03-09       Impact factor: 12.531

Review 8.  Clinical trial designs for predictive marker validation in cancer treatment trials.

Authors:  Daniel J Sargent; Barbara A Conley; Carmen Allegra; Laurence Collette
Journal:  J Clin Oncol       Date:  2005-03-20       Impact factor: 44.544

9.  The BATTLE trial: personalizing therapy for lung cancer.

Authors:  Edward S Kim; Roy S Herbst; Ignacio I Wistuba; J Jack Lee; George R Blumenschein; Anne Tsao; David J Stewart; Marshall E Hicks; Jeremy Erasmus; Sanjay Gupta; Christine M Alden; Suyu Liu; Ximing Tang; Fadlo R Khuri; Hai T Tran; Bruce E Johnson; John V Heymach; Li Mao; Frank Fossella; Merrill S Kies; Vassiliki Papadimitrakopoulou; Suzanne E Davis; Scott M Lippman; Waun K Hong
Journal:  Cancer Discov       Date:  2011-06-01       Impact factor: 39.397
  9 in total
  1 in total

1.  Scenario drafting for early technology assessment of next generation sequencing in clinical oncology.

Authors:  S E P Joosten; V P Retèl; V M H Coupé; M M van den Heuvel; W H van Harten
Journal:  BMC Cancer       Date:  2016-02-06       Impact factor: 4.430
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.